Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Georgia's Online Cancer Information Center

Find A Clinical Trial

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Status
Active
Cancer Type
Leukemia
Neuroblastoma
Sarcoma
Trial Phase
Phase I
Phase II
Eligibility
6 Months - 25 Years, Male and Female
Study Type
Treatment
NCT ID
NCT06395103
Protocol IDs
9999-01A (primary)
NCI-2024-04094
2023
2023-507178-41
2023-507178-41-00
jRCT2031250824
LIGHTBEAM-U01
MK-9999-01A
U1111-1295-3459
Study Sponsor
Merck Sharp and Dohme LLC

Summary

Substudy 01A is part of a platform study. The purpose of this study is to assess the
efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or
refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse large B-cell lymphoma
(DLBCL)/Burkitt lymphoma, or neuroblastoma and in pediatric and young adult participants
with Ewing sarcoma.

Eligibility

  1. For hematological malignancies: Confirmed diagnosis of B-precursor B-ALL or DLBCL/Burkitt lymphoma according to World Health Organization (WHO) classification of neoplasms of the lymphoid tissues.
  2. For solid tumor malignancies: Histologically confirmed diagnosis of neuroblastoma or Ewing sarcoma.
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.